Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.26 USD

2.26
817,652

+0.14 (6.60%)

Updated Aug 6, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer

by Zacks Equity Research

Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.

Zacks Equity Research

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

by Zacks Equity Research

Sage Therapeutics' pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntington's disease fails to meet the primary goal.

Zacks Equity Research

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

by Zacks Equity Research

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Zacks Equity Research

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

by Zacks Equity Research

Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.

Zacks Equity Research

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

by Zacks Equity Research

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.

Zacks Equity Research

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

by Zacks Equity Research

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.

Zacks Equity Research

New Strong Buy Stocks for November 15th

by Zacks Equity Research

FHI, RJF, ASTS, APLD and SPRO have been added to the Zacks Rank #1 (Strong Buy) List on November 15, 2024.

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -18.52% and 41.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -17.81% and 18.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 26.47% and 1.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -16.67% and 1.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 22.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 5.71% and 4.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of 22.50% and 10.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?

by Zacks Equity Research

Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of -28% and 84.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 36.11% and 11.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 633.33% and 278.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.

Zacks Equity Research

Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Penumbra (PEN) will likely report strong Neuro sales growth on the strength of its RED 72 (with the proprietary SENDit technology), RED 43 and BMX81.

Zacks Equity Research

What's in Store for Boston Scientific (BSX) in Q3 Earnings?

by Zacks Equity Research

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

by Zacks Equity Research

Outside the United States, Edwards Lifesciences (EW) TAVR sales growth will likely be driven by broad-based adoption of the SAPIEN platform.

Zacks Equity Research

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

by Zacks Equity Research

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Zacks Equity Research

Insulet (PODD) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.